PMID- 33146439
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 1522-7278 (Electronic)
IS  - 1520-4081 (Linking)
VI  - 36
IP  - 3
DP  - 2021 Mar
TI  - Syringin alleviates ovalbumin-induced lung inflammation in BALB/c mice asthma 
      model via NF-kappaB signaling pathway.
PG  - 433-444
LID - 10.1002/tox.23049 [doi]
AB  - Asthma is an allergic chronic inflammatory disease of the pulmonary airways, 
      characterized by the infiltration of white blood cells and release of 
      inflammatory cytokines of complex pathways linked to its pathogenesis. Syringin 
      extracted from various medicinal plants has been used extensively for the 
      treatment of inflammatory diseases. Hence, this study was conducted to further 
      explore the protective effects of the syringin in ovalbumin (OVA) induced-asthma 
      mice model. OVA-sensitized BALB mice were treated intraperitonealy with three 
      doses (25, 50 and 100 mg/kg) of the syringin which was validated by the 
      alteration in the immunoglobulin E (IgE) levels, cytokines levels, 
      histopathological evaluation inflammatory cell count, lung weight, nitrite (NO) 
      levels, oxidative stress biomarkers and gene markers. The treatment of syringin 
      intensely reduced the increased IgE, inflammatory cytokines, WBC count and 
      restored the antioxidant stress markers OVA stimulated animals. In addition, a 
      significant reduction in inflammation and mucus production was evidenced in 
      histopathological analysis which was further validated by suppression NF-kappaB 
      pathway activation by syringin. These results suggest that syringin may improve 
      asthma symptoms in OVA-induced mice by modulating NF-kappaB pathway activation.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Dai, Rui
AU  - Dai R
AD  - Department of Pediatric, The Second Affiliated Hospital of Anhui Medical 
      University, Hefei, China.
FAU - Niu, Manman
AU  - Niu M
AD  - Department of Pediatric, The Second Affiliated Hospital of Anhui Medical 
      University, Hefei, China.
FAU - Wang, Ningling
AU  - Wang N
AD  - Department of Pediatric, The Second Affiliated Hospital of Anhui Medical 
      University, Hefei, China.
FAU - Wang, Yan
AU  - Wang Y
AUID- ORCID: 0000-0003-1558-2712
AD  - Department of Pediatric, The Second Affiliated Hospital of Anhui Medical 
      University, Hefei, China.
LA  - eng
PT  - Journal Article
DEP - 20201104
PL  - United States
TA  - Environ Toxicol
JT  - Environmental toxicology
JID - 100885357
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Cytokines)
RN  - 0 (Glucosides)
RN  - 0 (NF-kappa B)
RN  - 0 (Phenylpropionates)
RN  - 9006-59-1 (Ovalbumin)
RN  - I6F5B11C96 (syringin)
SB  - IM
MH  - Animals
MH  - Anti-Asthmatic Agents/*pharmacology
MH  - Asthma/pathology
MH  - Cytokines/metabolism
MH  - Disease Models, Animal
MH  - Female
MH  - Glucosides/*pharmacology
MH  - Inflammation/pathology
MH  - Lung/drug effects
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - NF-kappa B/metabolism
MH  - Ovalbumin/adverse effects
MH  - Phenylpropionates/*pharmacology
MH  - Pneumonia/drug therapy
MH  - Signal Transduction/drug effects
OTO - NOTNLM
OT  - anti-allergic
OT  - anti-inflammatory
OT  - anti-oxidant
OT  - asthma
OT  - murine model
OT  - ovalbumin
OT  - syringin
EDAT- 2020/11/05 06:00
MHDA- 2021/03/05 06:00
CRDT- 2020/11/04 08:44
PHST- 2020/09/08 00:00 [received]
PHST- 2020/10/15 00:00 [accepted]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
PHST- 2020/11/04 08:44 [entrez]
AID - 10.1002/tox.23049 [doi]
PST - ppublish
SO  - Environ Toxicol. 2021 Mar;36(3):433-444. doi: 10.1002/tox.23049. Epub 2020 Nov 4.